Business Wire

MI-EATON

Share
Eaton's Innovative Safety Solutions Help Accelerate Electrified Vehicle Transition

Intelligent power management company Eaton today announced its comprehensive suite of safety-focused electrified vehicle (EV) technologies will be on display June 18-20 in Hall 10-A36 at The Battery Show Europe in Stuttgart, Germany.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240611322422/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Eaton plans to show its suite of safety-focused electrified vehicle (EV) technologies June 18-20 at The Battery Show Europe in Stuttgart, Germany. (Photo: Business Wire)

“While EV adoption continues to increase, we are helping our global customers meet the growing demand with innovative new technologies,” said Mark Schneider, president, Eaton’s eMobility business. “Safety is always a priority, whether the vehicle is powered by gasoline or electricity, and our EV solutions ensure occupants and the vehicle itself remain secure.”

Breaktor a pioneering high-voltage EV protection device

Eaton’s Breaktor® circuit protection technology combines the function of fuses, pyro switches, and contactors into a single coordinated and resettable device. As electric vehicle power levels increase, Breaktor solves the ever-increasing coordination challenge between fuses and contactors and offers extremely fast, safe and reliable protection for high-power battery and inverter systems.

3-in-1 battery vent valve improves battery pack leak testing

Eaton’s 3-in-1 battery vent valve is the first-to-market solution that is capable of three unique functions. In addition to passive and active venting, to provide overpressure relief for the vehicle’s battery pack, it includes an industry first battery-case leak-check mechanism.

It can open up during testing, allowing battery makers to completely leak-check the fully assembled battery pack with the valve in place. This provides customers with the peace of mind that all sealing surfaces of the battery pack are fully tested against water ingress. This Eaton-developed technology improves the safety of vehicles during normal operation and in the event of flooding situations.

The vent valve is precisely and flexibly designed to meet specific opening pressures and optimize venting. Its spring-based actuation technology allows Eaton to accommodate different opening pressure requirements with the same valve design to drive economies of scale.

Fuel tank isolation valve releases pressure in hybrid-electric vehicles

Eaton’s next-generation fuel tank isolation valve (FTIV) releases pressure in the gas tank of a hybrid-electric vehicle since the gas engine in a hybrid vehicle does not operate continuously. Pressure has to be released when the vehicle is in electric mode, and when refueling it’s important the tank is depressurized to avoid spit back.

High Power Lock Box terminals provide protection against the elements

Eaton’s High Power Lock Box (HPLB) terminals, which serve as the interface to a conductor and create a point where external circuits can be connected, are ideal for current and future EV solutions. They have numerous benefits over competitive solutions, including a space-saving profile, superior performance, cost savings, and reduced manufacturing complexity. They also provide efficiency, reliability and protection against the elements.

Eaton Bussmann series fuses optimized for high-powered electrified vehicles

Eaton Bussmann® series fuses feature ratings of up to 1,000 volts of direct current (VDC) and up to 600 amps, enabling them to meet the requirements for use in high-powered EVs.

Eaton's hybrid and EV fuses are designed to manage and protect the charging systems of electric commercial, passenger and high-performance vehicles such as sports cars and large sport-utility vehicles.

Learn more about Eaton’s EV solutions.

Eaton is an intelligent power management company dedicated to protecting the environment and improving the quality of life for people everywhere. We make products for the data center, utility, industrial, commercial, machine building, residential, aerospace, and mobility markets. We are guided by our commitment to do business right, to operate sustainably, and to help our customers manage power ─ today and well into the future. By capitalizing on the global growth trends of electrification and digitalization, we’re accelerating the planet’s transition to renewable energy sources, helping to solve the world’s most urgent power management challenges, and building a more sustainable society for people today and generations to come.

Eaton was founded in 1911 and has been listed on the New York Stock Exchange for more than a century. We reported revenues of $23.2 billion in 2023 and serve customers in more than 160 countries. For more information, visit www.eaton.com. Follow us on LinkedIn.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240611322422/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Compass Pathways Announces FDA Acceptance of IND Application for PTSD and Hosts Webinar on PTSD and TRD7.1.2026 12:30:00 CET | Press release

FDA Accepts Investigational New Drug (IND) Application for COMP360 for the treatment of post-traumatic stress disorder (PTSD), enabling initiation of late-stage trialCompass continues to advance commercial preparations to be launch-ready by the end of the year for COMP360 for treatment-resistant depression (TRD)Management will host webinar with KOL and industry leaders to discuss PTSD clinical trial and commercial preparations for TRD from 10:00-11:30 am ET on January 7th Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for COMP360, enabling the initiation of a late-stage clinical trial in patients with PTSD. Compass management, along with KOL and industry leaders, will host a webinar today to discuss the company’s clinical trial plans for PTSD, as well as commercial preparations f

Stallergenes Greer Expands Venom Immunotherapy Production Capacity With Acquisition of Entomon s.r.l.7.1.2026 11:07:00 CET | Press release

Stallergenes Greer, a global leader in allergy therapeutics, today announced that it has entered into an agreement to acquire Entomon s.r.l., an Italian company specialising in the production of certified stinging-insect venom extracts, notably of the Hymenoptera order, used for the manufacture of diagnostic preparations and Venom Immunotherapy (VIT). The transaction is expected to close by the end of January. Entomon, currently recognised as the only company in Europe capable of extracting pure venom from Hymenoptera insects, produces pharmaceutical-grade insect venom using proprietary techniques (Entomon Capillary Extracted Venom®) for medical use. Through this acquisition, Stallergenes Greer bolsters its venom manufacturing capabilities and supply of raw materials for life-saving VIT treatments, whilst safeguarding patient care continuity. Hymenoptera venom allergy is the most common trigger of severe anaphylaxis in adults1. According to the EAACI guidelines on venom immunotherapy,

ARIS Announces New CEO to Lead Agentic AI-led Strategy7.1.2026 10:00:00 CET | Press release

CEO Appointment ARIS, a global leader in process intelligence and transformation software, today announced the appointment of Guillaume Bacuvier as Chief Executive Officer. Guillaume will lead ARIS through its next phase of growth as a fully standalone company, accelerating its evolution from a market leader in Process Intelligence into a foundational platform for enterprises deploying and governing Agentic AI. Guillaume brings deep international leadership experience across technology, data, and software-enabled businesses, with a proven track record of scaling global platforms and leading complex organisations. After starting as a strategic consultant at Booz Allen Hamilton, Guillaume spent over a decade at Google, rising to Vice President in EMEA where he built and scaled some of Google’s largest data-driven businesses in Europe and held P&L responsibility across multiple countries. In the last decade, Guillaume has served as CEO of multi-continent, data-centric companies including

I Squared Capital Acquires Ramudden Global, a Leader in Traffic Management and Infrastructure Safety7.1.2026 09:00:00 CET | Press release

Acquisition will accelerate Ramudden’s ambitious growth plan across North America and Europe supported by strong infrastructure spending tailwinds I Squared Capital, a leading global infrastructure investment manager, today announced that, through its flagship fund, it has agreed to acquire Ramudden Global, from funds advised by Triton Partners (“Triton”), a leading European mid-market sector-specialist investor. Ramudden Global is a leading international provider of traffic management and infrastructure safety services supporting the maintenance and upgrade of essential transport and utility networks. The company operates more than 190 depots across 13 countries in Europe and North America delivering mission-critical services that help to ensure safety, regulatory compliance and continuity of service across road, utility and broader infrastructure works. This investment underscores I Squared Capital’s commitment to investing in essential, regulated, infrastructure businesses that unde

RoslinCT and BOOST Pharma Announce Strategic Manufacturing Agreement to Advance Cell Therapy for Infants with Osteogenesis Imperfecta7.1.2026 09:00:00 CET | Press release

RoslinCT, a global contract development and manufacturing organization (CDMO) specializing in advanced cell therapies, and BOOST Pharma, a clinical-stage biotechnology company developing first-in-class cell therapies for rare paediatric skeletal diseases, today announced a strategic manufacturing partnership to support the development of BOOST Pharma’s cell therapy, BT-101, for the treatment of infants with Osteogenesis Imperfecta (OI), also known as brittle bone disease. Under the service agreement, BOOST Pharma has transferred its manufacturing process to RoslinCT’s state-of-the-art facilities in Edinburgh, Scotland. The partnership will progress toward GMP manufacturing of starting materials and clinical drug product, supporting Phase III clinical development of BT-101. The therapy is an allogeneic mesenchymal stem cell (MSC) product designed to address the underlying cause of OI at the earliest stages of life. BOOST Pharma was founded on pioneering science originating from Karolins

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye